LT2001016A - Naujos natrio alendronato hidratinės formos, jų pagaminimo būdai ir jų farmacinės kompozicijos - Google Patents

Naujos natrio alendronato hidratinės formos, jų pagaminimo būdai ir jų farmacinės kompozicijos

Info

Publication number
LT2001016A
LT2001016A LT2001016A LT2001016A LT2001016A LT 2001016 A LT2001016 A LT 2001016A LT 2001016 A LT2001016 A LT 2001016A LT 2001016 A LT2001016 A LT 2001016A LT 2001016 A LT2001016 A LT 2001016A
Authority
LT
Lithuania
Prior art keywords
processes
manufacture
pharmaceutical compositions
alendronate
sodoum
Prior art date
Application number
LT2001016A
Other languages
English (en)
Other versions
LT4888B (lt
Inventor
Nina Finkelstein
Ramy Lidor-Hadas
Judith Aronhime
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of LT2001016A publication Critical patent/LT2001016A/lt
Publication of LT4888B publication Critical patent/LT4888B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LT2001016A 1998-08-27 2001-02-26 Naujos natrio alendronato hidratinės formos, jų pagaminimo būdai ir jų farmacinės kompozicijos LT4888B (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19

Publications (2)

Publication Number Publication Date
LT2001016A true LT2001016A (lt) 2001-10-25
LT4888B LT4888B (lt) 2002-02-25

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2001016A LT4888B (lt) 1998-08-27 2001-02-26 Naujos natrio alendronato hidratinės formos, jų pagaminimo būdai ir jų farmacinės kompozicijos

Country Status (30)

Country Link
US (2) US6281381B1 (lt)
EP (1) EP1107974B1 (lt)
JP (2) JP2002523514A (lt)
KR (2) KR20070034132A (lt)
AT (1) ATE334993T1 (lt)
AU (1) AU5698899A (lt)
BG (1) BG65329B1 (lt)
BR (1) BR9913472A (lt)
CA (1) CA2341459A1 (lt)
CZ (1) CZ2001629A3 (lt)
DE (1) DE69932620T2 (lt)
DK (1) DK1107974T3 (lt)
EA (1) EA002739B1 (lt)
EE (1) EE04552B1 (lt)
ES (1) ES2270613T3 (lt)
HR (1) HRP20010129A2 (lt)
HU (1) HUP0203078A3 (lt)
IL (1) IL141423A (lt)
IS (1) IS5864A (lt)
LT (1) LT4888B (lt)
LV (1) LV12720B (lt)
NO (1) NO20010957L (lt)
NZ (1) NZ510682A (lt)
PL (1) PL346347A1 (lt)
PT (1) PT1107974E (lt)
RO (1) RO122854B1 (lt)
SI (1) SI20581B (lt)
SK (1) SK2482001A3 (lt)
WO (1) WO2000012517A1 (lt)
YU (1) YU14701A (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
EA006053B1 (ru) * 2001-12-24 2005-08-25 Тева Фармасьютикал Индастриес Лтд. Твёрдая лекарственная форма, способ её изготовления и устройство
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) * 2003-10-14 2005-05-26 Pliva - Research And Development Ltd. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
KR20080083068A (ko) 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
DE602005016292D1 (de) * 2004-10-29 2009-10-08 Sandoz Ag Verfahren zur herstellung von glatiramer
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ576347A (en) * 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
JP2013510097A (ja) * 2009-11-03 2013-03-21 リウ、リー タンシノンｉｉａスルホン酸ナトリウム水和物、並びにその調製方法及び使用
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
WO1996039149A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
AU6148396A (en) 1995-06-06 1996-12-24 Merck & Co., Inc. Disodium alendronate formulations

Also Published As

Publication number Publication date
SK2482001A3 (en) 2002-01-07
NZ510682A (en) 2003-09-26
NO20010957L (no) 2001-04-26
WO2000012517A1 (en) 2000-03-09
CA2341459A1 (en) 2000-03-09
BG105292A (en) 2001-12-29
DK1107974T3 (da) 2006-10-30
JP2002523514A (ja) 2002-07-30
JP2009143955A (ja) 2009-07-02
BG65329B1 (bg) 2008-02-29
US6696601B2 (en) 2004-02-24
KR20070034132A (ko) 2007-03-27
NO20010957D0 (no) 2001-02-26
WO2000012517A9 (en) 2000-07-13
LV12720A (lv) 2001-09-20
HUP0203078A2 (hu) 2003-01-28
EP1107974A1 (en) 2001-06-20
EP1107974A4 (en) 2001-09-26
CZ2001629A3 (cs) 2001-08-15
DE69932620D1 (de) 2006-09-14
EA200100184A1 (ru) 2001-10-22
IL141423A (en) 2005-09-25
EA002739B1 (ru) 2002-08-29
YU14701A (sh) 2003-01-31
LT4888B (lt) 2002-02-25
ATE334993T1 (de) 2006-08-15
IL141423A0 (en) 2002-03-10
US20030065214A1 (en) 2003-04-03
HRP20010129A2 (en) 2005-04-30
IS5864A (is) 2001-02-26
AU5698899A (en) 2000-03-21
SI20581A (sl) 2001-12-31
PT1107974E (pt) 2006-10-31
ES2270613T3 (es) 2007-04-01
RO122854B1 (ro) 2010-03-30
EP1107974B1 (en) 2006-08-02
PL346347A1 (en) 2002-02-11
KR20010079701A (ko) 2001-08-22
EE200100126A (et) 2002-06-17
BR9913472A (pt) 2002-03-05
HUP0203078A3 (en) 2005-01-28
DE69932620T2 (de) 2006-12-14
EE04552B1 (et) 2005-10-17
US6281381B1 (en) 2001-08-28
LV12720B (en) 2002-02-20
SI20581B (sl) 2008-06-30

Similar Documents

Publication Publication Date Title
LV12720A (lv) Novel hydrate forms of alendronate sodium processes for manufacture thereof and pharmaceutical compositions thereof
PL339548A1 (en) Implant for uniting two fragments of fractured bone
AU7566601A (en) Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
WO2001039724A3 (en) Phosphonate compounds
ZA977524B (en) Process for the preparation of bone cements comprising active compound.
WO2004098617A3 (en) Controlled release composition containing a strontium salt
GB0015745D0 (en) Treatment of bone diseases
EP1119255A4 (en) NEW COMPOSITIONS AND METHOD FOR THE PREVENTION AND TREATMENT OF PROTOCOL DISEASES
HUP0303006A3 (en) Retinoids for the treatment of emphysema, process for their preparation and pharmaceutical compositions containing them
HUP0401141A3 (en) Crystalline forms of fluvastatin sodium, process for their preparation and pharmaceutical compositions containing them
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
HUP0302309A3 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity and for preparation of pharmaceutical compositions containing them
HUP0204005A3 (en) Novel forms of pravastatin sodium, process for their preparation and pharmaceutical compositions containing them
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
AU2000265107A1 (en) Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
ZA200101451B (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof.
HUP0402283A3 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine, process for their preparation and pharmaceutical compositions containing them
HK1034715A (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
GB0100092D0 (en) Treatment of degenerative diseases
HUP9800835A3 (en) Pharmaceutical composition for treatment of diseases of honey-bees caused by ascophaera apis
HU9801406D0 (en) Pharmaceutical compositions for treating and healing diseases of allergia and process for producing them
AU2001240529A1 (en) Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
UA32302A (uk) Спосіб усунення післяопераційних деформацій м'яких тканин

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20090827